NDAINHALATIONGAS
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Clinical Trials
16
Data completeness
5/8 — Partial
CARBON DIOXIDE, USP (carbon dioxide) by Martin Pharmaceuticals is x-ray contrast activity [moa]. Approved for vocal cord dysfunction, hypertrophic scar, burns and 9 more indications. First approved in 2024.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CARBON DIOXIDE, USP is an inhaled gas product approved in August 2024 as a radiographic contrast agent with X-ray contrast activity. It is indicated for a broad range of conditions including vocal cord dysfunction, burns, actinic keratosis, ARDS, hypoxia, migraine, and neonatal encephalopathy. The product works through gas-based imaging and therapeutic mechanisms that remain under clinical investigation across its diverse indication portfolio.
Growth
Early-stage growth product with moderate competitive pressure (30/100) and newly approved status presents opportunity for team expansion in commercial and medical affairs roles.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Worked on CARBON DIOXIDE, USP at Martin Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.